Targets › ITGB7
7 programs from 7 companies in 49 trials: 17 Phase 3, 17 Phase 2, 11 Phase 4, 4 Phase 1; Immunology, Oncology, Neurology; next expected readout Dec 2026.
Integrin ITGA4/ITGB7 (alpha-4/beta-7) (Peyer patches-specific homing receptor LPAM-1) is an adhesion molecule that mediates lymphocyte migration and homing to gut-associated lymphoid tissue (GALT) (Probable). Integrin ITGA4/ITGB7 interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. (UniProt, P26010)
Open in Phaseline: the race on ITGB7, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Takeda | Vedolizumab Integrin alpha-4/beta-7 inhibitor | ITGA4, ITGB7 | Phase 4 | Ulcerative Colitis; Crohn's Disease; Crohn's Disease (CD); Moderately to Severely Active Ulcerative Colitis … | May 2027 |
| The Cleveland Clinic | Natalizumab Integrin alpha-4/beta-7 inhibitor; Integrin alpha-4/beta-1 inhibitor | ITGA4, ITGB7, ITGB1 | Phase 4 | Multiple Sclerosis, Relapsing-Remitting | Jul 2027 |
| Roche | Afimkibart Anti-integrin α4β7 monoclonal antibody | ITGA4, ITGB7, IL22RA1 | Phase 3 | Moderately to Severely Active Ulcerative Colitis; Moderately to Severely Active Crohns Disease; Crohns Disease; Atopic Dermatitis … | Dec 2026 |
| Queen Mary University of London | Natalizumab Integrin alpha-4/beta-7 inhibitor; Integrin alpha-4/beta-1 inhibitor | ITGA4, ITGB7, ITGB1 | Phase 2 | Multiple Sclerosis | Oct 2027 |
| University of Michigan Rogel Cancer Center | Natalizumab Integrin alpha-4/beta-7 inhibitor; Integrin alpha-4/beta-1 inhibitor | ITGA4, ITGB7, ITGB1 | Phase 2 | Recurrent Diffuse Large B-Cell Lymphoma | May 2028 |
| Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | MORF-057 Selective integrin α4β7 inhibitor | ITGA4, ITGB7 | Phase 2 | Inflammatory Bowel Diseases | Sep 2028 |
| 7 Hills Pharma | Alintegimod α4β7 integrin antagonist | ITGA4, ITGB7 | Phase 1 | Advanced Cancer | Dec 2027 |
Ulcerative Colitis (11) Moderately to Severely Active Ulcerative Colitis (5) Crohn's Disease (4) Moderately to Severely Active Crohns Disease (3) Crohn Disease (2) Acute Lymphoblastic Leukemia (2) Atopic Dermatitis (2) Rheumatoid Arthritis (2) Inflammatory Bowel Diseases (2) Crohn's Disease (CD) (1) Pouchitis (1) Moderately to Severely Active Crohn's Disease (1)
antibody (3), mixed (3), small molecule (1)
Takeda (1) Roche (1) University of Michigan Rogel Cancer Center (1) Queen Mary University of London (1) 7 Hills Pharma (1) The Cleveland Clinic (1) Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.